ora™ Test

In partnership with Inti Labs

Test Introduction

A Revolution in Endometrial Receptivity Testing

ora^TMis the world’s first non-invasive endometrial receptivity test for identifying a patient’s optimal window of implantation (WOI). It assesses a combination of microRNA (miRNA) biomarkers in the bloodstream and physiological conditions to determine the status of a patient’s endometrium, providing information that can be used to optimize the timing of implantation.

This genetic test offers a non-invasive approach to identifying the ideal timing for embryo transfer, increasing the likelihood of successful implantation and pregnancy. Unlike traditional methods that involve invasive endometrial biopsies, the ORA test uses just a blood sample, giving patients a comfortable and reliable alternative.

Why choose ora™?

ora™ uses novel miRNA biomarkers present in the blood to accurately identify a patient’s WOI.

This unique endometrial receptivity test delivers fast and reliable results, helping to increase the successful pregnancy rate for IVF patients with a history of implantation faillure.

ora™ analyzes miRNA biomarkers in the blood, removing the need for an invasive and uncomfortable endometrial biopsy procedure.
ora™ analyzes microRNA (miRNA) biomarkers in a stable blood sample with over 95% accuracy.

ora™ is able to account for both average and shortened post-receptive windows, meaning patients only require one mock cycle regardless of what stage their endometrium is.
Our non-invasive blood-based test allows for sample collection on the day of embryo transfer, streamlining your journey and minimizing disruptions.

ora™ as been shown to have >95% accuracy in predicting endometrial receptivity, offering a stable solution with a more comfortable testing procedure.
ora™ analyzess close to 300 miRNA biomarkers that target over 1,000 endometrial receptivity-related genes to accurately identify the optimal time for embryo transfer.
Addtitional blood samples can be collected to account for potential shifts in implantation timing, enchancing the accuracy of your results and minimizing the need for re-testing.

Medical treatment has to be individualised and can only be rendered after adequate assessment of your condition through appropriate clinical examination, and after discussion with your doctor. You should not rely on the information provided herein. Please note that the contents of this page are provided on the understanding that no surgical or medical advice or recommendation is being rendered.

How it Works

Patient Story

A Patient’s Journey: A Life-Changing Experience with Vaginitis Screening

Lisa, aged 37, had her first cycle in April 2023 which had a poor blastulation rate and the single Day 3 fresh embryo transfer did not result in a successful pregnancy. A second treatment cycle in December 2023 failed to acquire a good quality blastocyst.

With precious and limited embryos remaining, ora^TMwas recommended for the third cycle. Following analysis, it was found that the patient was pre-receptive, with a recommended adjusted timing of 144 hours. A low-risk, frozen mosaic embryo was successfully transferred and implanted on Sept 9, 2024. Now, Lisa has a ongoing healthy pregnancy.